

Index

NOTE: Page numbers of chapter titles are in **bold face** type.

ACTINOMYCIN D, 216

Active immunotherapy, 173-184

Acute erythroleukaemia, diagnosis, 121

Acute leukaemia—

cellular morphology, cytochemistry and fine structure, **49-91**

chemotherapy, 127-161

clinical presentation of, 115-118

cytological diagnosis, 132-136

diagnosis and clinical picture of, 115-126

epidemiology, **3-21**

genetic vulnerability to, 39

granulocytic, 59-75

immunological approaches to the treatment of, **165-184**

kinetics of 'normal cells', 109-110

laboratory findings at diagnosis, 199-201

lymphoblastic, 51-59

monitoring and follow-up of treatment, **153-154**

observations on the aetiology of, **23-43**

physical findings at diagnosis, 199

present and future developments of immunological treatment of, 180-184

programmes aimed at cure of, 130-131

recommended therapy for, 143-148

supportive treatment, 155-160

Acute leukaemia in children, **189-223**

clinical course, 204-206

clinical symptoms, 198-199

clinical symptoms and system involvement, 206-214

current methods of treatment, 217-223

differential diagnosis, 201-202

neurological symptoms, 212-213

Acute leukaemia in children (*continued*)

prognostic factors, 202-204

renal involvement, 211

therapy, 214-223

Acute lymphatic leukaemia—

diagnosis, 120

model for immunotherapy, 175-180

Acute monocytic leukaemia, diagnosis, 119-120

Acute myeloblastic leukaemia, diagnosis, 118-119

Acute myelocytic leukaemia, diagnosis, 119

Acute myeloid leukaemia—

diagnosis, 119

therapy, 143-146

Acute myelomonocytic leukaemia, 75-83

diagnosis, 119

Acute plasma-cell leukaemia, diagnosis, 121

Acute reticulum-cell leukaemia, diagnosis, 120

Adoptive immunotherapy, 167-173

Aetiology of acute leukaemia, observations on the, **23-43**

Age of patient, as guide to therapy, 135-136

Alkylating agents in treatment of leukaemia, 216

Anaemia—

and leukaemia, 206-207

aplastic-type, and leukaemia, 123

megaloblastic, and acute leukaemia, 117-118

Animals—

chemical leukomogenesis in, 34-37

experimental leukaemia in, 33-39

naturally occurring leukaemia in, 31-33

Animals (*continued*)

- radiation-induced leukaemia in, 33-34
- viral leukomogenesis in, 37-39
- Antibiotics in treatment of leukaemia, 216
- Antileukaemic drugs, 131-132
- Antimetabolites in leukaemic therapy for children, 214-215
- Arabinosyl cytosine, 215
- Auer rods, 71-73, 82
- Azurophilic granules, 70

BLAST cells—

- leukaemic in peripheral blood, 102-103
- 'non-proliferating' in bone marrow, 101-102
- 'non-proliferating' leukaemic, existence of, 104-108
- 'proliferating', 98-101
- studies of leukaemic, 95-98
- Blood, leukaemic blast cells in peripheral, 102-103
- Bone marrow, 'non-proliferating' blast cells in, 101-102
- Bovine leukaemia, 31

CARDIAC complications in leukaemic children, 211

- Cats, malignancies in, 32-33
- Cell culture, human leukaemic, 30
- Cells (*see* Blast cells; Cytology; Ultrastructure)
- Central nervous system leukaemia, treatment, 150-153
- Chemical leukomogenesis, 26-27
- in animals, 34-37
- Chemotherapy of acute leukaemia, **127-161**
- Children, acute leukaemia in, 189-223
- incidence of mortality, 189-190
- (*see also* Acute leukaemia in children)
- Chloroleukaemia in mice, 34
- Chronic leukaemia, epidemiology, 3-21
- Cortisone, 215
- Curative therapy, cytokinetic basis for, 141-143
- Cyclophosphamide, 216
- Cytochemistry, 52-54
- of acute granulocytic leukaemia, 63-68
- of acute myelomonocytic leukaemia, 77-79
- of erythraemic myelosis, 84-88
- Cytology—
- acute granulocytic leukaemia, 59-63
- acute myelomonocytic leukaemia, 76-77
- diagnosis of acute leukaemias, 132-136
- erythraemic myelosis, 84
- light microscope, 51-52

DAUNOMYCIN, 216

- Death, recording of causes of, 5-17
- Dental problems, clinical presentation in acute leukaemia, 116-117
- Diagnosis and clinical picture of acute leukaemia, **115-126**
- Diagnosis of acute leukaemia, findings at, 198-201
- Differential diagnosis of leukaemia, 118-126, 201-202
- DNA-synthesis time of 'proliferating' blast cells, 98
- Dogs, malignancies in, 32
- Domestic animals, malignancies in, 32
- Drugs, antileukaemic, 131-132

EAR, nose and throat, clinical signs in acute leukaemia, 116

- Enzymes, in treatment of leukaemia, 217
- Epidemiology of acute (and chronic) leukaemias, 3-21
- Erythraemic myelosis, 83-91
- Esterase cytochemistry, 65
- Experimental leukaemia—
- in animals, 33-39
- in man, 30-31

FEVER, and leukaemia, 210

- G₁-duration, 100
- G₂-duration, 99-100
- Generation time of leukaemic blast cells, 100-101
- Genetic factors in pathogenesis of leukaemia, 194-195
- Genetic vulnerability to acute leukaemia, 39
- Glandular fever, and acute leukaemia, 117
- Granulocytic leukaemia, acute, 59-75
- HAEMORRHAGE, and leukaemia, 116, 207-208
- Hormones in treatment of leukaemia, 215
- ³H-thymidine studies of leukaemic blast cells, 96-98
- Human leukaemic cell culture, 30

- IMMUNOLOGICAL approaches to the treatment of acute leukaemia, **165-184**
- Immunological aspects of leukaemia, 197

- Immunological data relevant to leukomogenesis, 40-42
- Immunological investigations in man, 28-30
- Immunotherapy—
 active, 173-184
 acute lymphoblastic leukaemia model for, 175-180
 adoptive, 167-173
 passive, 165-167
- Infections—
 and leukaemia, 192-194, 210-211
 treatment of in acute leukaemia, 156-160
- KINETICS—
 of leukaemic blast cells in man, 95-110
 of 'normal' cells in acute leukaemia, 109-110
- LEUCOCYTES, ultrastructure in acute lymphoblastic leukaemia, 54-59
- Leucocytosis, and leukaemia, 208-209
- Leucokinesis, and leukaemia, 196-197
- Leucopenia, and leukaemia, 208-209
- Leukaemia—
 acute (*see* Acute leukaemia)
 age and sex incidence, 198
 diagnosis of difficult cases, 121-126
 differential diagnosis of type, 118-126
 experimental in animals, 33-39
 experimental in man, 30-31
 naturally occurring in animals, 31-33
 naturally occurring in man, 23-30
 pathogenesis of, 191-197
 treatment for central nervous system, 150-153
- Leukaemias, classification of, 5-6
- Leukaemic blast cells—
 generation time, 100-101
³H-thymidine studies of, 96-98
 kinetics of, 95-110
 mitotic index studies of, 95-96
- Leukaemoid reactions, 124-126
- Leukomogenesis—
 chemical, 26-27
 in animals, 34-37
 immunological data, 40-42
 problems relating to viral, 41-42
 radiation, in man, 24-26
 viral, in animals, 37-39
 in man, 27-30
- Life, quality of, in leukaemic patients, 160
- Lymphatic leukaemia, reactions resembling, 124
- Lymphoblastic leukaemia, acute, 51-59
 therapy for, 146-148
- MALIGNANT disease, leukaemoid reactions occurring in the course of, 124
- Man—
 chemical leukaemogenesis in, 26-27
 immunological investigations in, 28-30
 kinetics of leukaemic blast cells in, 95-110
 radiation leukaemogenesis in, 24-25
 viral leukaemogenesis in, 27-30
- Marrow regeneration, and leukaemia, 123-124
- Megaloblastic anaemia, and acute leukaemia, 117-118
- Meningeal leukaemia, 148-153
- 6-Mercaptopurine, 215
- Metabolic activity and leukaemia, 196
- Methotrexate, 214
- Mitotic index studies of leukaemic blood cells, 95-96
- Mitotic time of leukaemic blast cells, 98
- Monitoring of treatment for acute leukaemia, 153-154
- Monocytes, ultrastructure of normal, 79-80
- Mononucleosis, clinically benign, 124-126
- Morphology of leukaemia in children, 190-191
- Mortality, secular trend of leukaemia, 7-14
- Myeloid leukaemias, reactions resembling, 124
- Myelomonocytic leukaemia, acute, 75-83
- Myelosis erythraemic, 83-91
- 'NORMAL' cells in acute leukaemia, kinetics of, 109-110
- ORTHOPAEDIC cases, and acute leukaemia, 117
- Osseous changes, and leukaemia, 209
- PASSIVE immunotherapy, 165-167
- Pathogenesis of leukaemia, 191-197
 environmental factors, 191-194
 genetic factors, 194-195
- Pathophysiology of leukaemia, 196-197
- Plant alkaloids in treatment of leukaemia, 216-217
- Prednisone, 215
- Pre-leukaemia, 198
- Pulmonary complications in leukaemia, 211-212
- Puromycin, 216
- RADIATION, as cause of leukaemia, 191-192
- Radiation-induced leukaemia in animals, 33-34

- Radiation leukomogenesis in man, 24-26
Radiations, ionising, 127
Recording of leukaemia deaths, 5-14
 source of age-biased, 14-17
Remission—
 induced, in acute leukaemia, 128
 techniques for inducing, 136-137
 techniques for maintenance of in acute
 leukaemia, 129-130, 137-141
 therapy for patients not achieving, 146
Renal involvement in leukaemic children,
 211
Reticulosis, and leukaemia, 122
- SKELETAL changes, and leukaemia, 209
Skin disease, clinical presentation in acute
 leukaemia, 116
Supportive treatment, 155-160
- THERAPY—
 centralisation of, 160
 for acute leukaemia in children, 214-223
 (*see also* Chemotherapy)
Thrombocytopenic purpura, 116
Toxic agents, and leukaemia, 194
Transfusion therapy, 127, 155-156
- ULTRASTRUCTURE of leucocytes—
 acute lymphoblastic leukaemia, 54-59
 acute myelomonocytic leukaemia, 79-83
 erythraemic myelosis, 88-91
 granulocytic leukaemia, 68-75
- VINCRISTINE, 216
Viral leukomogenesis, 27-30
 in animals, 37-39
 problems relating to, 41-42

Index

Note: Page numbers of chapter titles are in **bold face** type.

- ADHESION, platelet, 246-247, 285-288
 - technique for measuring, 370-371
- Adenine nucleotide metabolism, platelet, 257-259
- Adenosine—
 - in thromasthenic platelets, 389
 - its phosphates and analogues, 254
- ADP receptors, 243
- Adrenal cortical steroids, in treatment of I.T.P., 334-335
- Adrenaline receptors, 244
- Age and sex, in thrombocythaemia, 340
- Aggregation—
 - abnormal platelet, 373-375
 - of inhibitors, classification, 298-303
 - platelet, 288-290, 296-297
 - in Glanzmann thrombasthenia, 386-387
 - test for estimating, 371
- Anaemia, aplastic, transfusion therapy, 403-404
- Antibody, evidence for existence of in I.T.P., 328-329
- Anticoagulants and platelet life span, 317
- Anti-inflammatory agents, 254
- Arterial thrombosis, 269-273
 - role of fibrin in, 271-272
- Arteries—
 - platelet thrombi in coronary and cerebral, 272-273
 - role of damaged vessel wall, 269-270
- BERNARD-SOULIER syndrome, 359-361
- Biochemistry, platelet, 255-263
- Bleeding, post-operative and traumatic, transfusion therapy, 405
- Bleeding disorders—
 - thrombocytopathia, 375-376
 - platelet adhesion in, 285-287
- Bleeding tendency in thrombocythaemia, mechanism of, 344-346
- Bleeding time, 283-284
- Blood—
 - changes in I.T.P., 332
 - fresh whole, in transfusion therapy, 395-396
- Bone marrow appearances in I.T.P., 331
- CALCIUM and magnesium in thrombasthenia, 389
- Chelators, 254
- Chemotherapy for treatment of thrombocythaemia, 347-348
- Clot retraction, 292
- Clotting—
 - platelet contribution to, 297
 - role of thrombasthenic platelets in, 390
- Clotting factors—
 - activation of, 277
 - removal of activated, 277-278
- Coagulation tests, 371
- Compatibility, immunologic, 318-319

- Cryogenic methods in transfusion therapy, 400
- Cyclic AMP, compounds increasing platelet, 254
- DF³²P, 315
- Drugs—
 immunosuppressive in treatment of I.T.P., 336
 investigations into action of, 297–298
 Drugs that effect platelet behaviour, **295–304**
- ELECTRON microscopy, 386
- Endothelium, adhesion of platelets to, 296
- Enzymes in Glanzmann thrombasthenia, 383–390
- FACTOR 3—
 impaired platelet availability, 375
 availability, tests for, 371
- Fibrinogen, platelet, 255
- Fibrinolysis, contribution to thrombus, 276–277
- GLANZMANN thrombasthenia, **383–390**
 clinical features, 383, 384
 diagnostic laboratory finding, 384–385
 hereditary features, 383
 microscopy studies, 385–386
 release phenomenon in, 387–388
 treatment, 384
- Granulocytopenia, management of drug-induced, 436–437
- HAEMATOLOGICAL features of thrombocythaemia, 341–346
- Haemodialysis and platelets, 417–418
- Haemorrhagic diseases, platelet aggregation in, 289–290
- Haemostasis, role of platelets in, 369–370
- Heart valves, prosthetic, and platelets, 418–422
- Histamine excretion in organ rejection, 432–433
- 5-hydroxytryptamine in thrombasthenia, 389
- Hyperadhesiveness, 288
- IDIOPATHIC thrombocytopenic purpura (I.T.P.), **327–336**
 bone marrow appearances in, 331
 clinical picture, 331–332
 diagnosis, 332–334
 functional studies of, 329–331
- I.T.P. (*continued*)
 hereditary thrombocytopenia resembling, 363–365
 transfusion therapy, 404
 treatment, 334–336
- Immunoglobulin adsorption in thrombasthenia, 389
- Inhibitors—
 classification of aggregation, 298–303
 specific, of release reaction, 254–255
- KINETICS, platelet, and lifespan, **307–321**
- LABELS, preparation of platelet, 317–318
- Laboratory tests for thrombocythaemia, 341–343, 344
- Leukaemia, transfusion therapy, 402–403
- L-fucose in thrombasthenia, 389
- Life-span curves, 319–321
- Lipids, platelet, 256–257
- MEG-HEGGLIN anomaly in thrombocytopenia, 363
- Megakaryocytopoiesis, 307–309
- Membrane—
 platelet, 238–244
 chemical and biochemical composition of the surface, 240–242
 surface charge, 242–243
 surface receptors, 243–244
 morphology of surface, 239–240
- Membrane stabilisers, 255
- Metabolic inhibitors, 254
- Metabolism, platelet, 259–262
 adenine nucleotide, 257–259
- Microscopy studies in Glanzmann thrombasthenia, 385–386
- PHASE contrast microscopy, 385–386
- Physiology, platelet, 245–255
- Plasma, platelet rich, in transfusion therapy, 396
- Plastic bags in platelet physiology, 317
- Platelet abnormalities, diagnosis of, 378–379
- Platelet 'activation' on endothelium, effect of, 432
- Platelet adhesion, 246–247, 285–288
 decreased, 372–373
 in vivo test for, 284
- Platelet aggregation, 247–249, 288–290
 abnormal, 373–375
 agents inhibiting clotting, 433
 and mechanical motion, 249
 immunological stimulus for, and release of vasoactive amines, 431

- Platelet aggregation (*continued*)
 in Glanzmann thrombasthenia, 386-387
 in vitro studies on, 270-271
 tests for estimating, 371
- Platelet behaviour, effect of drugs on, 295-304
- Platelet concentrates, in transfusion therapy, 397-398
- Platelet constituents, 262-263
- Platelet counts in renal transplants, 432
- Platelet defects—
 acquired, 376
 drug induced, 376-377
 illustrative cases, 379
- Platelet factor-3 availability tests, 291-292
- Platelet function, 245-246
 in thrombocytopenia, 416-417
 induction and inhibition of the, 252-254
 thrombosis and its control, 420-422
- Platelet function disorders, 371-377
 nomenclature, 377-378
 transfusion therapy, 404
- Platelet function tests, 283-293, 370-371
- Platelet immunology, 390
- Platelet kinetics and life span, 307-321
- Platelet labels, 313-317
- Platelet life span—
 in thrombasthenia, 389
 studies, factors that affect, 317-321
- Platelet morphology, bleeding disorders associated with abnormalities in, 375-376
- Platelet production, 309-317
- Platelet refractoriness, 249
- Platelet release reaction, inhibitors of, 302-303
- Platelet storage, 398-400
- Platelet survival and prosthetic heart valves, 419
- Platelet transfusion, as treatment for I.T.P., 336
- Platelet transfusion therapy, 395-407
- Platelets—
 biochemical abnormalities in thrombasthenia, 388-390
 direct evidence for participation of in organ rejection, 432-433
 haemodialysis and, 417-418
 in organ transplantation, 425-438
 in prostheses and pumps, 413-422
 interaction of and glass, 284-285
 membrane, 238-244
 membrane, physiology and biochemistry, 235-263
 populations in thrombasthenia, 389
 preparations containing viable, 395-398
 prosthetic heart valves and, 418-422
 pumps and, 413-417
- Platelets (*continued*)
 responses to tissue injury, 431
 role of in haemostasis, 369-370
 role of in immunopathic processes associated with rejection, 431-434
 role of thrombasthenic in clotting, 390
 ultrastructure of the resting, 236-238
- Plateletpheresis, in transfusion therapy, 398
- Postoperative platelet adhesiveness, 287
- Prostheses, heart valves and platelets, 418-422
- Prosthetic heart valves, platelet survival in patients, 419
- Proteins—
 in Glanzmann thrombasthenia, 388-389
 platelet, 255
- Pumps and platelets, 413-417
- Purpura, idiopathic thrombocytopenic, 327-336
 history, 327-328
- RADIOACTIVE phosphorus, 315
 in treatment of thrombocythaemia, 347
 α -receptor antagonists, 254
- Release reaction, platelet, 249-252
- Released substances and their possible function, 251-252
- Renal allograft rejection—
 acute, 425-428
 chronic, 429-431
 histologic, physiologic and immunologic patterns of, 425-431
 second-set, 428-429
- Renal transplantation—
 magnitude of clinical problem, 434-436
 thrombocytopenia following, 434-438
- Rotating loop test, 291
- SCREEN filtration pressure test, 290-291
- Selenomethionine, labelling of, 316
- Serotonin, labelling of, 316
- Serotonin receptors, 243-244
- Shape changes, platelet, 246
- Sialic acid in thrombasthenia, 389
- Sodium chromate, labelling of, 316-317
- Sodium sulphate, labelling of, 316
- Splenectomy, as treatment for I.T.P., 335-336
- Splenic atrophy as complication of thrombocythaemia, 346
- Steroids, adrenal cortical, in treatment of I.T.P., 334-335
- Storage, platelet, 398-400

- THROMBASTHENIA, Glanzmann, 383-390
- Thrombocythaemia, 339-355
- clinical course, 348-354
 - clinical features, 340-346
 - haematological features, 341-346
 - incidence of, 339-340
 - symptoms and signs, 340
 - treatment, 346-348
- Thrombocytopathia, 369-379
- Thrombocytopenia—
- extracorporeal circulation and, 413-416
 - following renal transplantation, 434-438
 - platelet function and, 416-417
 - management of patients with drug-induced, 437-438
 - with absent radius, 362-363
- Thrombocytopenia, hereditary, 359-366
- resembling I.T.P., 363-365
- Thrombosis—
- blood flow and, 272
 - platelet contribution to arterial and venous, 267-279
 - therapeutic implications, 278-279.
- Thrombosthenin, 255-256
- Thrombotic disorders—
- platelet adhesion in, 287
 - platelet aggregation in, 290
- Transfusion, platelet, as treatment for I.T.P., 336
- Transfusion therapy—
- clinical practice, 401-405
 - complications of, 405-407
 - platelet, 395-407
- Transplantation, platelets in organ, 425-438
- VASCULAR disease, platelet adhesion in, 288
- Venous thrombosis, 274-278
- role of fibrin in, 275-276
- WISKOTT-ALDRICH syndrome, 361-362

